Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables RefundsShares Issued
Ratios

Ligand Pharmaceuticals (LGND) Long-Term Debt Repayments: 2010-2023

Historic Long-Term Debt Repayments for Ligand Pharmaceuticals (LGND) over the last 4 years, with Jun 2023 value amounting to $76.9 million.

  • Ligand Pharmaceuticals' Long-Term Debt Repayments rose 28.20% to $76.9 million in Q2 2023 from the same period last year, while for Jun 2023 it was $337.8 million, marking a year-over-year increase of 25.00%. This contributed to the annual value of $76.9 million for FY2023, which is 70.55% down from last year.
  • Ligand Pharmaceuticals' Long-Term Debt Repayments amounted to $76.9 million in Q2 2023, which was up 104.15% from $37.6 million recorded in Q3 2022.
  • Over the past 5 years, Ligand Pharmaceuticals' Long-Term Debt Repayments peaked at $203.2 million during Q1 2020, and registered a low of $2.4 million during Q3 2021.
  • In the last 3 years, Ligand Pharmaceuticals' Long-Term Debt Repayments had a median value of $59.9 million in 2022 and averaged $70.5 million.
  • In the last 5 years, Ligand Pharmaceuticals' Long-Term Debt Repayments plummeted by 46.45% in 2021 and then soared by 1,482.43% in 2022.
  • Quarterly analysis of 5 years shows Ligand Pharmaceuticals' Long-Term Debt Repayments stood at $27.3 million in 2019, then reached $19.0 million in 2020, then tumbled by 46.45% to $2.4 million in 2021, then skyrocketed by 1,482.43% to $37.6 million in 2022, then climbed by 28.20% to $76.9 million in 2023.
  • Its Long-Term Debt Repayments was $76.9 million in Q2 2023, compared to $37.6 million in Q3 2022 and $59.9 million in Q2 2022.